Liposomal doxorubicin
Showing 1 - 25 of 2,187
Breast Cancer With Liposomal Doxorubicin Regimen
Recruiting
- Breast Cancer
- +4 more
- Liposomal doxorubicin containing regimen
-
Hangzhou, Zhejiang, ChinaSecond Affiliate Hospital of Zhejiang University
Feb 7, 2023
Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance
Not yet recruiting
- Metastatic Leiomyosarcoma
- +5 more
- Computed Tomography
- +3 more
- (no location specified)
Feb 2, 2023
Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)
Not yet recruiting
- Kaposi Sarcoma
- HIV-1-infection
- Pegylated liposomal doxorubicin
- Paclitaxel
- (no location specified)
Jan 20, 2023
Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)
Recruiting
- Angiosarcoma Metastatic
- Abraxane combined with liposomal doxorubicin
-
Guangzhou, Guangdong, ChinaXing Zhang
Sep 4, 2022
Platinum-resistant Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- pegylated liposomal doxorubicin
- (no location specified)
Aug 2, 2023
Relapsed Sarcomas Trial in Cleveland (Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil))
Not yet recruiting
- Relapsed Sarcomas
- Disulfiram
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Apr 18, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Colon Cancer Liver Metastasis Trial in United States (Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution,
Terminated
- Colon Cancer Liver Metastasis
- Lyso-Thermosensitive Liposomal Doxorubicin
- +2 more
-
Los Angeles, California
- +3 more
Sep 15, 2022
Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)
Recruiting
- Ovarian Cancer Recurrent
- IN10018
- +2 more
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Science and Peking Un
Aug 23, 2023
Advanced Malignant Tumors Trial in Shanghai (doxorubicin HCl liposome injection)
Recruiting
- Advanced Malignant Tumors
- doxorubicin hydrochloride liposome injection
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 28, 2022
Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)
Completed
- Breast Cancer
- Trastuzumab and non-pegylated liposomal doxorubicin
-
Paris, France
- +3 more
Feb 8, 2022
Triple Negative Breast Cancer (TNBC) Trial in United States (Combination of liposomal doxorubicin)
Not yet recruiting
- Triple Negative Breast Cancer (TNBC)
- Combination of liposomal doxorubicin
-
Elizabeth, New Jersey
- +7 more
Jul 13, 2023
Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 19, 2022
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)
Active, not recruiting
- Invasive Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
Breast Cancer Trial in Shanghai (sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin)
Recruiting
- Breast Cancer
- sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
May 22, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients Trial in Guangzhou (Blood sampling)
Recruiting
- Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients
- Blood sampling
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Dec 21, 2021
Desmoid Tumor Trial in GuangZhou (Liposome doxorubicin, Saline Solution)
Recruiting
- Desmoid Tumor
- Liposome doxorubicin
- Saline Solution
-
GuangZhou, Guangdong, ChinaSun Yat-sen University cancer center
Sep 29, 2022
Breast Cancer Trial in Prague, Haifa, Candiolo (drug, radiation, device)
Withdrawn
- Breast Cancer
- ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
- +2 more
-
Prague, Czechia
- +2 more
Mar 29, 2022
Solid Tumors Trial in Milano, Bellinzona, Chur (AZD2281, liposomal doxorubicin)
Active, not recruiting
- Solid Tumors
- AZD2281
- liposomal doxorubicin
-
Milano, Italy
- +2 more
Nov 17, 2021
Breast Cancer Trial in Guandong (pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H))
Recruiting
- Breast Cancer
- pegylated liposomal doxorubicin (PLD)
- +5 more
-
Guandong, Guangdong, ChinaSunyat-sen Memorial Hospital
Feb 17, 2022
Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)
Completed
- Advanced Ovarian Cancer
- Olaparib
- Pegylated Liposomal Doxorubicin
-
Sabadell, Barcelona, Spain
- +7 more
Jan 25, 2023
Ovarian Cancer Trial in Indianapolis, Madison (Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120)
Terminated
- Ovarian Cancer
- Doxil (Pegylated Liposomal Doxorubicin)
- BIBF 1120
-
Indianapolis, Indiana
- +1 more
Feb 14, 2022